Surrogate markers in antiangiogenesis clinical trials

Novel antiangiogenic agents currently being developed may ultimately be more effective against solid tumours and less toxic than cytotoxic chemotherapy. As a result of the early clinical trials of angiogenesis inhibitors, investigators are beginning to appreciate the complexity of targeting angiogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, D W, McConkey, D J, Abbruzzese, J L, Herbst, R S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394225/
https://www.ncbi.nlm.nih.gov/pubmed/12838293
http://dx.doi.org/10.1038/sj.bjc.6601035
_version_ 1782155368085848064
author Davis, D W
McConkey, D J
Abbruzzese, J L
Herbst, R S
author_facet Davis, D W
McConkey, D J
Abbruzzese, J L
Herbst, R S
author_sort Davis, D W
collection PubMed
description Novel antiangiogenic agents currently being developed may ultimately be more effective against solid tumours and less toxic than cytotoxic chemotherapy. As a result of the early clinical trials of angiogenesis inhibitors, investigators are beginning to appreciate the complexity of targeting angiogenesis and the realisation that developing clinically useful antiangiogenic therapy will be more challenging than originally thought. It is now apparent that new methods and surrogate markers to assess these agents' biological activity are crucial for their successful development. This review summarises the currently available clinical data on the development of surrogate markers of angiogenesis inhibitors.
format Text
id pubmed-2394225
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23942252009-09-10 Surrogate markers in antiangiogenesis clinical trials Davis, D W McConkey, D J Abbruzzese, J L Herbst, R S Br J Cancer Review Novel antiangiogenic agents currently being developed may ultimately be more effective against solid tumours and less toxic than cytotoxic chemotherapy. As a result of the early clinical trials of angiogenesis inhibitors, investigators are beginning to appreciate the complexity of targeting angiogenesis and the realisation that developing clinically useful antiangiogenic therapy will be more challenging than originally thought. It is now apparent that new methods and surrogate markers to assess these agents' biological activity are crucial for their successful development. This review summarises the currently available clinical data on the development of surrogate markers of angiogenesis inhibitors. Nature Publishing Group 2003-07-07 2003-07-01 /pmc/articles/PMC2394225/ /pubmed/12838293 http://dx.doi.org/10.1038/sj.bjc.6601035 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Review
Davis, D W
McConkey, D J
Abbruzzese, J L
Herbst, R S
Surrogate markers in antiangiogenesis clinical trials
title Surrogate markers in antiangiogenesis clinical trials
title_full Surrogate markers in antiangiogenesis clinical trials
title_fullStr Surrogate markers in antiangiogenesis clinical trials
title_full_unstemmed Surrogate markers in antiangiogenesis clinical trials
title_short Surrogate markers in antiangiogenesis clinical trials
title_sort surrogate markers in antiangiogenesis clinical trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394225/
https://www.ncbi.nlm.nih.gov/pubmed/12838293
http://dx.doi.org/10.1038/sj.bjc.6601035
work_keys_str_mv AT davisdw surrogatemarkersinantiangiogenesisclinicaltrials
AT mcconkeydj surrogatemarkersinantiangiogenesisclinicaltrials
AT abbruzzesejl surrogatemarkersinantiangiogenesisclinicaltrials
AT herbstrs surrogatemarkersinantiangiogenesisclinicaltrials

Ejemplares similares